Zealand Pharma Shares Tumble on Weight-Loss Drug Data

Danish biotech firm Zealand Pharma experienced a significant stock market downturn, with shares falling 22% following the release of new data on its weight-loss drug candidate, survodutide. The disappointing results were presented by its collaboration partner, Boehringer Ingelheim, at a recent diabetes conference in the United States.

The Phase 3 trial data indicated that while survodutide led to an average weight loss of 16.6% among participants, a substantial number experienced adverse side effects. Approximately one in five participants reported experiencing nausea, vomiting, and diarrhea to a degree that prompted them to cease treatment. These side effects were more prevalent than anticipated.

“

The stock is falling 22 percent from the morning after the new data, which showed more side effects than expected with the use of the weight loss agent survodutide.

Analysts have pointed to potential issues with the trial's methodology. According to a comment from an analyst at Jefferies, the initial design of the study did not allow participants to reduce their dosage. Although this was later amended, the analyst believes the change likely had a limited impact. This aspect of the trial design may have contributed to the observed side effects and the overall disappointing outcomes.

“

Even though the agent caused an average weight loss of 16.6 percent, about every fifth participant in the phase 3 trial experienced side effects in the form of nausea, vomiting, and diarrhea to such an extent that they chose to stop treatment.

Zealand Pharma originally discovered and developed the survodutide molecule. The company subsequently entered into a licensing agreement with Boehringer Ingelheim, granting the German pharmaceutical giant the rights to conduct pivotal clinical trials and market the drug. Under this agreement, Zealand Pharma is entitled to a share of future sales and milestone payments.

The company is also engaged in a similar collaboration with Roche for another weight-loss drug candidate, petrelintid. However, the recent setback with survodutide casts a shadow over its development pipeline and its financial projections, as evidenced by the sharp decline in its stock value.

“

The disappointing trial results can partly be attributed to the way the study was designed.